About Us

About Array

Values 
At Array, we embrace three core values that guide our day-to-day activities:

    1. Integrity and transparency in what we do and how we do it
    2. A sense of urgency and creativity in bringing benefit to patients
    3. The knowledge to achieve our critical objectives

Array Today
Array markets in the United States BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation as detected by an FDA-approved test.* Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), larotrectinib and LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics), and ARRY-797. Ganovo® (danoprevir, partnered with Roche) was recently approved in China.

*Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.